14.03.2014 • News

Codexis sells Hungarian operations to Intrexon Corporation

Codexis today announced the sale of its Hungarian subsidiary to Intrexon Corporation. The transaction closed on March 13, with a purchase price of US$ 1.5 million. No proprietary Codexis materials or intellectual property were included in the transaction. "We are very pleased with this transaction," said John Nicols, President and CEO of Codexis. "We were able to transfer our dedicated and talented employees in Hungary to Intrexon and to monetize one of our assets as part of the wind down of our biofuels business."

Company

Codexis

200 Penobscot Drive
Redwood City

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.